AAP
XENE icon

Arax Advisory Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Arax Advisory Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27
Closed -$1.21K – 4380
2025
Q4 		$1.21K Sell
27
-92
-77% -$3.86K ﹤0.01% 3436
2025
Q3 		$4.78K Buy
+119
New +$4.19K ﹤0.01% 2886
2024
Q4 		– Sell
-3
Closed -$119 – 2781
2024
Q3 		$119 Hold
3
– – ﹤0.01% 2547
2024
Q2 		$117 Buy
+3
New +$120 ﹤0.01% 2482

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Arax Advisory Partners's XENE Position: Q1 2026 in Review

Arax Advisory Partners sold out of Xenon Pharmaceuticals (XENE) in Q1 2026, closing a stake of 27 shares — an estimated $1.21K sold.

Arax Advisory Partners first reported a position in XENE in Q2 2024 and held it in 4 quarters. The position peaked at $4.78K in Q3 2025. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Arax Advisory Partners reported no remaining Xenon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 27 Xenon Pharmaceuticals shares in Q1 2026, an estimated $1.21K.
  • Arax Advisory Partners first reported a position in Xenon Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Arax Advisory Partners's Xenon Pharmaceuticals position peaked at $4.78K in Q3 2025.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.